Aktien Sensor

Alnylam Pharmaceuticals has announced its partnership with the Alliance for Genomic Discovery, a move expected to enhance the company’s clinical capabilities, pipeline diversification, and regulatory engagement, ultimately improving the efficacy and…

Alnylam Pharmaceuticals is accelerating towards profitability, bolstered by a strengthened capital structure and robust market momentum, driven by its innovative RNAi therapeutics and growing TTR franchise.

Alnylam Pharmaceuticals Inc. is experiencing promising growth, with recent successes in its Ambutra program and strong analyst ratings, despite a setback in a trial for its hypertension RNAi drug.

Alnylam Pharmaceuticals’ stock price is on a rollercoaster ride, but its financial woes, including a negative price-to-earnings ratio and overvalued price-to-book ratio, raise concerns about the company’s long-term prospects.

Alnylam Pharmaceuticals presented advancements in RNAi therapeutics for cardiovascular disease at the European Society of Cardiology 2025 Congress.

Alnylam Pharmaceuticals is pioneering a new era in cardiovascular disease treatment with its innovative RNAi therapeutics, set to unveil groundbreaking data at the European Society of Cardiology Congress 2025.

Alnylam Pharmaceuticals has seen record-breaking growth, with its stock price reaching an all-time high and several major investment firms upgrading their ratings and price targets.

Alnylam Pharmaceuticals’ groundbreaking Amvuttra treatment has driven significant growth, surpassing a $50 billion market value and exceeding analyst estimates, with a bright future predicted.

Alnylam Pharmaceuticals has surpassed $50 billion in market capitalization and is poised to dominate the market with its Amvuttra treatment, crushing earnings estimates and reaching a new all-time high in stock price.

Alnylam Pharmaceuticals has gained a positive rating from Truist Securities, citing the company’s promising pipeline and growth prospects in the treatment of human diseases.